The levels of collagenase, tissue inhibitor of metalloproteinases-1 (TIMP-1), collagenase approximately TIMP-1 complexes and glycosaminoglycan (GAG) in sequential samples of synovial fluid aspirated from patients with osteoarthritis. 1995

T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK.

OBJECTIVE Collagen turnover in connective tissues is thought to be controlled by the balance between the levels of interstitial collagenase and tissue inhibitor of metalloproteinases (TIMP-1). The aim of this study was to measure the level of total collagenase (MMP-1), TIMP-1, collagenase approximately TIMP-1 complex and glycosaminoglycan (GAG) in sequential samples of osteoarthritic knee synovial fluid from well documented patients to determine if these parameters changed with time and correlated with clinical indices. METHODS Twenty-one patients were recruited and randomly allocated to receive tiaprofenic acid, indomethacin or naproxen. Total collagenase, TIMP-1, collagenase approximately TIMP-1 complex and GAG were measured in 80 osteoarthritic synovial fluids taken over a period of six months. RESULTS The majority of fluids contained a molar excess of TIMP-1 over collagenase, although in seven fluids collagenase was present in excess; six of these samples were from a single patient. GAG levels were relatively unchanged over the six months studied. CONCLUSIONS The levels of collagenase and TIMP-1 varied between patients and over time in individual patients. No collagenase approximately TIMP-1 complex was found in any fluid. There was no significant difference in the median levels of collagenase, TIMP-1 or GAG in the different treatment groups. High levels of collagenase were found in one patient with a crystal related disease. These immunoassays give valuable information on the levels of collagenase and TIMP-1 in individual patients with time and may help to determine the mechanisms controlling the turnover of cartilage collagen in different arthritides.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007719 Knee Joint A synovial hinge connection formed between the bones of the FEMUR; TIBIA; and PATELLA. Superior Tibiofibular Joint,Joint, Knee,Joint, Superior Tibiofibular,Knee Joints,Superior Tibiofibular Joints,Tibiofibular Joint, Superior
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009288 Naproxen An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. Aleve,Anaprox,Methoxypropiocin,Naprosin,Naprosyn,Naproxen Sodium,Proxen,Sodium Naproxenate,Synflex,Naproxenate, Sodium,Sodium, Naproxen
D010003 Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. Arthritis, Degenerative,Osteoarthrosis,Osteoarthrosis Deformans,Arthroses,Arthrosis,Arthritides, Degenerative,Degenerative Arthritides,Degenerative Arthritis,Osteoarthritides,Osteoarthroses
D011422 Propionates Derivatives of propionic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxyethane structure. Propanoate,Propanoic Acid,Propionate,Propanoates,Propanoic Acid Derivatives,Propanoic Acids,Propionic Acid Derivatives,Propionic Acids,Acid, Propanoic,Acids, Propanoic,Acids, Propionic,Derivatives, Propanoic Acid,Derivatives, Propionic Acid
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated

Related Publications

T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
March 1993, Arthritis and rheumatism,
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
June 1999, Rheumatology (Oxford, England),
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
January 1992, Matrix (Stuttgart, Germany). Supplement,
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
September 1994, Biochemical and biophysical research communications,
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
October 1990, Matrix (Stuttgart, Germany),
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
January 1992, FEBS letters,
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
January 1990, Virchows Archiv. B, Cell pathology including molecular pathology,
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
September 1996, The Journal of rheumatology,
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
January 2003, Surgery today,
T E Cawston, and V Curry, and S Ramsey, and I M Clark, and V A Kyle, and A Adebajo, and B Silverman, and T Daymond, and B L Hazleman
October 1986, The British journal of dermatology,
Copied contents to your clipboard!